{"schema_version":"secwatch.filing_event.v1","accession":"0001588978-22-000003","form_type":"8-K","ticker":"PRCT","cik":"0001588978","company_name":"PROCEPT BioRobotics Corp","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.304564+00:00","generated_at":"2026-06-22T09:03:17.662054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PROCEPT BioRobotics Q3 revenue $20.3M (+135% YoY), raises 2022 guidance to ~$72.5M","bullets":["Total revenue $20.3M, +135% YoY; US system rev $9.8M (+95%), handpiece $8.0M (+267%).","Net loss $22.6M vs $14.1M prior year; Adjusted EBITDA loss $18.3M.","FY2022 revenue guidance raised to ~$72.5M (110% growth) from $66-68M; gross margin 50-51%.","New $52M five-year loan on Oct 10 retired $50M facility; reduces annual interest ~$2.8M.","Multi-system national contract with Providence for AquaBeam Robotic Systems announced Sept 19."],"urls":{"canonical":"https://secwatch.observer/filing/0001588978-22-000003","json":"https://secwatch.observer/filing/0001588978-22-000003.json","markdown":"https://secwatch.observer/filing/0001588978-22-000003.md","text":"https://secwatch.observer/filing/0001588978-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1588978/000158897822000003/0001588978-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1588978/000158897822000003/prct-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:03:17.662054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d2abca758643ae387c22ffa5c6a76ad2ce142bf","claim":"PROCEPT BioRobotics Corp reported for the quarter ended September 30, 2022 results: revenue $20.3 million. Guidance raised.","evidence_excerpt":"care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2022. Recent Highlights • Total Revenue of $20.3 million for the third quarter of 2022, an increase of 135% compared to the prior year period • U.S. system and rental revenue of $9.8 million for the third quarter of 2022, an increase","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1588978/000158897822000003/0001588978-22-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended September 30, 2022"},{"label":"Revenue","value":"$20.3 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}